|
Deca and Dianabol
Deca durabolin (nandrolene decanoate), or simply deca, is a great anabolic steroid that is used to gain strength and add mass. It is also a medically favorable steroid since it can be used to reduce joint problems and helps on osteoporosis. It increases calcium and potassium in the body which aids muscle growth and function. This is so because these ions help in release of insulin and transmitting nerve signals. The former helps in increasing the body mass and the latter effect increases strength. It can also be used during radiotherapy of patients with laryngeal cancer since it increases the sensitivity of laryngeal cells to radiotherapy. It can also be used to treat anemia associated with kidney failure.
Patients with breast cancer, diabetes, liver maladies, cardiovascular disease and any kidney problems need to verify first if deca usage is safe for them. Pregnant and nursing women should avoid using it. Also people on growth hormone medication, finasteride or or warfarin should not use deca durabolin because it tends to interact with it.
Deca and dianabol are used together in a mass cycle to elicit maximum muscle gain. Deca or nandrolone decanoate is administered as an intra muscular injection. The drug should also be kept away from bright light such as sunlight and should not be exposed to below freezing temperatures either. The best temperature for storing it is from 15 to 300C.
Nandrolene decanoate is banned in the US and also by the athletic organizations such as the International Olympic Committees for use in athletes. However, its medical benefits give it an advantage. Deca and dianabol usage together is also quite safe as both of them stack well and have few side effects though in excessive amounts, decadurabolin may produce a number of side effects including acne, hair loss, difficulty in passing urine and even impotence in men.
If things go wrong, depression, gastrointestinal discomfort, bleeding and weight gain may occur. In such a case, a physician should be immediately consulted. In children it may promote bone maturation but may fail to increase linear extension of the bone causing them to have a small stature. It may also lead to irregular growth and sexual development in children. If consumed by pregnant women, it may cause masculinization of the fetus.
For therapeutic uses, usually 4 mg of the steroid are prescribed to be taken orally. Doses may be higher if the purpose of use is loss of fat or building muscles. Hemoglobin and serum lipids should be periodically monitored during use.
Articles:
- Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary
- Former Idun Management team to expand efforts in liver
disease and oncology
SAN DIEGO, July 30 /PRNewswire/ -- Conatus Pharmaceuticals Inc.
announced today that Conatus acquired the Idun Pharmaceuticals
subsidiary of Pfizer Inc. Financial terms were...
- Charles River Announces Mutual Termination of Acquisition Agreement with WuXi PharmaTech
- – Board of Directors Approves $500 Million Stock
Repurchase Plan –
– Special Stockholder Meeting Canceled –
– Second-Quarter Earnings Release and Conference Call
Rescheduled –
WILMINGTON, Mass.--(BUSINESS...
- Novartis Vaccines Launches Fluvirin Vaccine in US Market
- From EquityBites (July 30, 2010)
Healthcare solutions supplier Novartis Vaccines (NYSE:NVS) stated
on Thursday that the company has commenced the shipment of
approximately 40m doses of Fluvirin vaccine to the US to support
the seasonal influenza...
- Amgen's Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38
- Second Quarter 2010 Revenue Increased 2 Percent to $3.8
Billion Second Quarter 2010 GAAP Earnings Per Share Unchanged at
$1.25 Adjusting for the Impact of a Weaker Euro, 2010 Total Revenue
Guidance Revised to Slightly Below $15.1 Billion 2010...
- Merck Announces Second-Quarter 2010 Financial Results
- Second-Quarter 2010 Non-GAAP EPS
of $0.86, Excluding Certain Items; Second-Quarter GAAP EPS of
$0.24
Key Pharmaceutical Products,
Consumer Care and Animal Health Deliver Strong Performance
Merger Integration Achieving
Strategic Intent; Synergy...
- FDA Advisory: Avoid Unintentional Exposure of Children and Pets to Evamist
- ROCKVILLE, Md., July 29, 2010--The U.S. Food and Drug
Administration is warning that inadvertent exposure to Evamist
through skin contact with patients using this product has the
potential for adverse effects in children and pets.
Evamist contains...
- FDA Advisory: Avoid Unintentional Exposure of Children and Pets to Evamist
- ROCKVILLE, Md., July 29, 2010--The U.S. Food and Drug
Administration is warning that inadvertent exposure to Evamist
through skin contact with patients using this product has the
potential for adverse effects in children and pets.
Evamist...
- Novartis Vaccines Launches Fluvirin Vaccine in US Market
- From EquityBites (July 30, 2010)
Healthcare solutions supplier Novartis Vaccines (NYSE:NVS) stated
on Thursday that the company has commenced the shipment of
approximately 40m doses of Fluvirin vaccine to the US to support
the seasonal...
- FDA MedWatch - Cubicin (daptomycin): Drug Safety Communication - Risk of Eosinophilic Pneumonia
- ROCKVILLE, Md., July 29, 2010-ISSUE: FDA notified healthcare
professionals and patients about the potential for developing
eosinophilic pneumonia during treatment with Cubicin (daptomycin),
an intravenous antibacterial drug indicated for use in...
- Sanofi Said to Be Preparing Genzyme Bid
- Sanofi Said To Be Preparing Genzyme Bid [Boston Herald]
From Boston Herald (MA) (July 29, 2010)
July 28--Sanofi-Aventis SA Chief Executive Chris Viehbacher has
support from his board of directors to offer as much as $70 a share
for Genzyme, or about...
- Appeals Court Rules Gemzar Patent Invalid
- Appeals Court Rules Gemzar Patent Invalid: Lilly, Which may
appeal panel's decision, could lose exclusivity to drug this fall
[The Indianapolis Star]
From Indianapolis Star (IN) (July 29, 2010)
July 29--Same courtroom, same lawyers, same legal...
- Sanofi-Aventis Q2 Net Up 61 Percent
- From Associated Press (July 29, 2010)
PARIS -- Drugmaker Sanofi-Aventis SA said net profit rose 61
percent to (EURO)1.7 billion ($2.2 billion) in the second quarter,
thanks to lower restructuring costs, but warned that earnings may
fall for the...
- AstraZeneca 2Q Profit Up 22 Pct
- From Associated Press (July 29, 2010)
LONDON -- AstraZeneca PLC doubled its share buyback program on
Thursday after posting strong second quarter results and revealing
that a key new drug -- its blood thinner Brilinta -- has been given
a thumbs up...
- Bayer Increases Sales And Earnings In The Second Quarter
- MaterialScience leaves the crisis behind Bayer increases sales
and earnings in the second quarter Sales grow by 14.6 percent to
EUR 9,179 million / EBITDA before special items up 8.6 percent to
EUR 1,917 million / Core earnings per share increase by...
- Q2/2010: Merck KGaA Profit After Tax Jumps 70% to EUR 187 Million
- Total revenues increase 16% to record EUR 2.2 billion
Rebif® sales up 4% to EUR 402 million
Erbitux® sales rise 23% to record EUR 210 million
Liquid Crystals revenues soar 50% to record EUR 284
million
2010 Group outlook with Millipore:...
- Astrazeneca Q2 Profits Up 22 Percent
- From Associated Press (July 29, 2010)
LONDON -- AstraZeneca PLC has reported a 22 percent rise in second
quarter net profit and has also revealed that a key new drug -- its
blood thinner Brilinta -- has been given a thumbs up by an...
- Sanofi-Aventis Q2 Net Up 61 Percent
- From Associated Press (July 29, 2010)
PARIS -- Drugmaker Sanofi-Aventis SA said net profit rose 61
percent to (EURO)1.7 billion ($2.2 billion) in the second quarter,
thanks to lower restructuring costs, but warned that earnings may
fall for the...
- Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune(R) Antibody Technology through 2023
- TARRYTOWN, N.Y. and TOKYO, July 28 /PRNewswire-FirstCall/ --
Regeneron Pharmaceuticals, Inc. ("Regeneron"; Nasdaq: REGN) and
Astellas Pharma Inc. ("Astellas"; Headquarters: Tokyo, Japan;
President & CEO: Masafumi Nogimori) announced today...
- FTC Testimony: Stopping ?Pay-for-Delay? Drug Settlement Agreements is a Top Competition Priority
- New Data Show the Number of Potential Anticompetitive
Settlements is on the Rise
WASHINGTON, July 27, 2010 - In testimony today before the U.S.
House of Representatives Committee on the Judiciary, Subcommittee
on Courts and Competition Policy, the...
- Wyeth Hormone Drug Case Opens In Philadelphia
- Wyeth Hormone Drug Case Opens In Philadelphia [The Philadelphia
Inquirer]
From Philadelphia Inquirer (PA) (July 28, 2010)
July 28--Before a packed house in a shoe box of a City Hall
courtroom Tuesday, attorneys Rainey Booth and Beth A....
- Pfizer Starts Social-Media Channel On Popular Site
- Pfizer Starts Social-Media Channel On Popular Site: Offerings to
include corporate news and science insight [The Day, New London,
Conn.]
From Day, The (New London, CT) (July 28, 2010)
July 28--Pfizer Inc., in a first for a regulated...
- Millipore Corporation Announces Change of Control and Right of Holders to Require Purchase of Its 5.875% Senior Notes Due 2016
- BILLERICA, Mass.--(BUSINESS WIRE)--Jul 27, 2010 - Millipore
Corporation, a leading provider of technologies, tools and services
for the global life science industry, announced previously that it
was acquired (the “Acquisition”) by Merck...
- Momenta Pharmaceuticals Provides Update Regarding Generic Lovenox Litigation
- CAMBRIDGE, Mass., Jul 27, 2010 (GlobeNewswire via COMTEX News
Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a
biotechnology company specializing in the characterization and
engineering of complex drugs, today provided an update regarding...
- Court Places No Restrictions On Generic Lovenox
- From Associated Press (July 27, 2010)
CAMBRIDGE, Mass. -- Biotechnology company Momenta
Pharmaceuticals Inc. said Tuesday a federal court placed no
restrictions on the sale of a generic version of Sanofi-Aventis
SA’s Lovenox, an injected drug...
- Alcon's Net Profit Up To $670 Million In Second Quarter
- Alcon's Net Profit Up To $670 Million In Second Quarter [Fort
Worth Star-Telegram, Texas]
From Fort Worth Star-Telegram (TX) (July 27, 2010)
July 27--Alcon said Monday that its second-quarter net profit rose
to $670 million, or $2.21 per share,...
- FDA Questions New Astrazeneca Blood Thinner
- From Associated Press (July 26, 2010)
WASHINGTON -- Federal health regulators say an experimental blood
thinner from AstraZeneca PLC appears effective, though study
results in the U.S. did not match those seen abroad.
London-based AstraZeneca has...
- GSK to Revamp Basis for Bonuses
- GSK to Revamp Basis for Bonuses [The News And Observer, Raleigh,
N.C.]
From News & Observer (Raleigh, NC) (July 27, 2010)
July 27--GlaxoSmithKline will revamp the way it pays U.S. drug
salespeople next year, tying bonuses to customer service...
- Teva Reports Strong Second Quarter 2010 Results Driven by Growth in All Businesses
- -- European Sales Grew 10% in Local Currencies
--
JERUSALEM--(BUSINESS WIRE)--Jul 27, 2010 - Teva Pharmaceutical
Industries Ltd. (NASDAQ: TEVA) today reported results for the
quarter ended June 30, 2010.
Second Quarter
Highlights:
Quarterly...
- Teva 2Q Profit Climbs 53 Percent
- From Associated Press (July 27, 2010)
NEW YORK -- Teva Pharmaceutical Industries said its second-quarter
net income leapt 53 percent as the biggest generic drug company in
the world launched a pair of new products.
Teva is based in Israel, but most...
- Alcon Posts 12.5 Percent Rise in Second Quarter Sales
- Second Quarter
Highlights
Sales increased to $1.89
billion (+11.3 percent organic growth, +12.5 percent
reported)
Adjusted operating income
rose 19.5 percent (+18.8 percent reported)
Adjusted diluted EPS
increased 14.4 percent to $2.22...
- Onyx Posts Positive Results For New Cancer Drug
- From Associated Press (July 26, 2010)
EMERYVILLE, Calif. -- Onyx Pharmaceuticals Inc. on Monday reported
positive clinical trial results for its cancer drug candidate,
saying it worked for some multiple myeloma patients who have seen
other...
- FTC Pushed Watson Subpoena, Denies Info Disclosure
- From Associated Press (July 23, 2010)
NEW YORK -- The Federal Trade Commission has accused Watson
Pharmaceuticals Inc. of delaying an investigation into a potential
"pay-for-delay" deal on a generic sleep disorder drug.
On Thursday, the FTC again...
- Sanofi-Aventis, Genzyme Discuss Possible Acquisition: Wall Street Journal
- From Canadian Press DataFile (July 23, 2010)
INDIANAPOLIS -- Shares of Genzyme Corp. soared Friday after a
report was published that French pharmaceutical company
Sanofi-Aventis is interested in the biotechnology drug maker.
The Wall Street...
- Gilead to Offer $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock
- FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul 26, 2010 - Gilead
Sciences, Inc. (Nasdaq:GILD) today announced its intention to
offer, subject to market and other conditions, approximately $1.1
billion principal amount of convertible senior notes due 2014...
- FDA Approves Larger Dose Of Pfizer's Aricept
- From Associated Press (July 25, 2010)
NEW YORK -- Drug makers Eisai Inc. and Pfizer Inc. said on Saturday
that government regulators have given them permission to make a
larger dose of its Alzheimer's disease drug Aricept for patients
who have...
- Almirall signs a co-promotion agreement with Pfizer to commercialise Conbriza in Spain, a new therapeutic option to treat osteoporosis
- This agreement enables Almirall to reinforce its core business
in Spain for the coming year
Conbriza® increases the bone density and reduces the risk of
vertebral and non-vertebral fractures in postmenopausal women at
increased risk of...
- European Medicines Agency recommends restricting the use of modafinil
- Doctors and patients advised to use modafinil for treatment of
narcolepsy only; all other indications to be removed from product
information
LONDON, July 22, 2010 - The European Medicines Agency has
recommended restricting the use of...
- Forest Settles Patent Dispute Over Namenda
- From Associated Press (July 22, 2010)
NEW YORK -- Drug developers Forest Laboratories Inc. and Merz GmbH
& Co. KGaA said Thursday they have settled a patent lawsuit
with companies they sued over the drug Alzheimer’s drug
Namenda.
Forest,...
- FDA Was Stymied In Records Search At Johnson And Johnson Plant
- FDA Was Stymied In Records Search At Johnson And Johnson Plant
[The Philadelphia Inquirer]
From Philadelphia Inquirer (PA) (July 22, 2010)
July 22--Just a month after a top executive of Johnson &
Johnson promised a "cooperative and transparent...
- Cialis' Success Fuels Lilly Push For New Men's Health Drugs
- Cialis' Success Fuels Lilly Push For New Men's Health drugs [The
Indianapolis Star]
From Indianapolis Star (IN) (July 23, 2010)
July 23--Eli Lilly and Co., which helped turn impotence drug Cialis
into a household name, is moving aggressively to...
|
